A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor

Advanced Malignant Solid Tumor Clinical Trial

Official title:

A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The Anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06166472
• Other study ID #: AK132-101
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: December 12, 2023
• Est. completion date: July 24, 2026

Study information

• Verified date: December 2023
• Source: Akeso
• Contact: Zhifang Yao, M.D.
• Phone: +86-0760-89873999
• Email: clinicaltrials[@]akesobio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 72
• Est. completion date: July 24, 2026
• Est. primary completion date: April 24, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. The subjects voluntarily participated in the study with full informed consent and signed written informed consent form.

2. Males or females aged = 18 to = 75 years at the time of signing informed consent.

3. Histologically and/or cytologically confirmed locally advanced unresectable or metastatic malignant solid tumors.

4. The interval between the end of the last systemic anti-tumor treatment and the first dose should be at least 3 weeks.

5. Subjects in the dose expansion phase are required to provide tumor tissue samples.

6. At least one measurable tumor lesion per RECIST v1.1.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

8. Life expectancy = 3 months.

9. Adequate organ function as assessed in the laboratory tests.

10. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective contraception measures during the study drug administration and within 120 days after the last dose. Male patients with female partners of childbearing potential must agree to take effective contraception measures during the study drug administration and within 120 days after the last dose.

Exclusion Criteria:

1. There is active or untreated brain metastases,Meningeal metastases, spinal cord compression, or leptomeningeal disease.

2. Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage (= 1/month).

3. Patients who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening.

4. gastrointestinal perforation or gastrointestinal fistula within 6 months before the first dose.

5. clinically significant bleeding symptoms or a clear tendency to bleed within 4 weeks before the first dose.

6. Active malignant tumors within the past 3 years, except for tumors in this study and scured local tumors.

7. History of hemolytic anemia due to any cause within 3 months before the first dose of study drug.

8. Have a history of defects in red blood cell or hemoglobin production or metabolism.

9. Major surgery other than the diagnosis of solid tumors within 28 days prior to the first dose or major surgery is expected during the study.

10. Clinically significant cardiovascular or cerebrovascular disease.

11. Presence of = Grade 2 peripheral neuropathy as defined by NCI CTCAE v5.0.

12. Presence of active diverticulitis.

13. Patients with serious neurological or psychiatric disorders.

14. Pregnant or lactating women.

15. Patients who received palliative local therapy for any tumor lesions within 2 weeks prior to the first dose;and Chinese herbal medicine or traditional Chinese medicinal products with anti-tumor indications within 2 weeks prior to the first dose.

16. Serious adverse reactions in subjects who have previously received anti-PD-1/PD-L1/CTLA-4 or any other immunotherapy or immuno-oncology (IO) drug.

17. Patients who require systemic treatment with glucocorticoids (> 10 mg/day prednisone or equivalent) or other immunosuppressive drugs within14 days prior to the first dose.

18. Unresolved toxicities during prior anti-tumor therapy with the exception of alopecia/pigmentation.

19. Subjects with a known history of severe hypersensitivity to other monoclonal antibodies. A known history of allergy or hypersensitivity to AK132 or any of its components.

20. Previous use of any antineoplastic drug targeting the CD47-SIRPa pathway or Claudin18.2.

21. Active autoimmune disease requiring systemic treatment within 2 years prior to the start of study treatment, or autoimmune diseases that may relapse or require scheduled treatment as judged by the Investigator.

22. Known active pulmonary tuberculosis.

23. Patients with active hepatitis B or active hepatitis C.

24. Known medical history of immunodeficiency or positive HIV test.

25. Known presence of interstitial lung disease or noninfectious pneumonitis that is currently symptomatic or requires prior systemic glucocorticoid therapy that, in the judgment of the Investigator, may affect the assessment or management of toxicity related to study treatment.

26. Patients with active infection, including those requiring intravenous antibiotics or antifungal therapy for 2 weeks prior to first dose, and unexplained fever during screening (CTCAE=1, except those determined by the investigator to be neoplasmic).

27. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.

28. Live vaccines were administered within 28 days prior to the first dose or were planned to be administered during the study period.

29. Concurrent participation in another clinical study, unless it is an observational, non-interventional clinical study or the follow-up period of an interventional study.

30. Any condition that, in the opinion of the Investigator, may result in a risk when receiving the study drug, or would interfere with the evaluation of the study drug or the safety of patients, or the interpretation of the study results.

Related Conditions & MeSH terms

• Advanced Malignant Solid Tumor
• Neoplasms

Intervention

Drug:
• AK132
IV infusion, specified dose on specified days.

Locations

Country	Name	City	State
China	Hunan Provincial Cancer Hospital	Changsha	Hunan
China	Fujian Provincial Cancer Hospital	Fuzhou	Fujian
China	Southern Medical University Nanfang Hospital	Guangzhou	Guangdong
China	Sun Yat-Sen University Cancer Center, Guangzhou, China	Guangzhou	Guangdong
China	The Second Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong
China	Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital	Wuhan	Hubei
China	Xiangyang Central Hospital	Xiangyang	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Akeso

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	dose-limiting toxicity (DLT)?adverse event(AE)?serious adverse event(SAE)	incidence and severity of DLT, adverse events (AE), serious adverse events (SAE)	Up to 2 years
Primary	Maximum tolerated dose (MTD),RP2D	Maximum tolerated dose (MTD), Recommended dose for phase II trial	Up to 2 years
Secondary	Pharmacokinetic	The PK parameters include serum concentrations of AK132 at different timepoints after AK132 administration.	Up to 2 years
Secondary	Immunogenicity assessmen	The immunogenicity of AK132 will be assessed by summarizing the number and percentage of subjects who develop detectable antidrug antibodies (ADAs).	Up to 2 years
Secondary	Objective response rate (ORR)	ORR is the proportion of subjects with CR or PR based on RECIST v1.1	Up to 2 years
Secondary	Duration of response (DoR)	Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first.	Up to 2 years
Secondary	Disease control rate (DCR)	DCR is defined as the proportion of subjects with CR, PR, or SD (based on RECIST Version 1.1).	Up to 2 years
Secondary	Time to response (TTR)	Time to response (TTR) is defined as the time from the start of the treatment to the first objective tumor response observed for patients who achieved CR or PR (based on RECIST Version 1.1).	Up to 2 years
Secondary	Progression-free survival (PFS)	PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST Version 1.1).	Up to 2 years
Secondary	Overall survival (OS)	OS defined as the time from the first dose to death from any cause.	Up to 2 years